Overview of Zika virus (ZIKV) infection in regards to the Brazilian epidemic

Autor(es)

Slavov, S. N. ^{[1, 2]} ; Otaguiri, K. K. ^{[2, 3]} ; Kashima, S. ^{[2, 3]} ; Covas, D. T. ^{[1, 2]}

Afiliação do(s) autor(es)

^[1] Univ Sao Paulo, Fac Med Ribeirao Preto, Dept Clin Med, Ribeirao Preto, SP - Brazil

^[2] Univ Sao Paulo, Fac Med Ribeirao Preto, Hemoctr Ribeirao Preto, Ribeirao Preto, SP - Brazil

^[3] Univ Sao Paulo, Fac Ciencias Farmaceut, Dept Anal Clin Toxicol & Bromatol, Ribeirao Preto, SP - Brazil

• Tipo de documento: Artigo Científico
• Fonte: Brazilian Journal of Medical and Biological Research; v. 49, n. 5 2016.
• Citações Web of Science: 29

Resumo

Zika virus (ZIKV), a mosquito-borne flavivirus, belongs to the Flaviviridae family, genus Flavivirus. ZIKV was initially isolated in 1947 from a sentinel monkey in the Zika forest, Uganda. Little clinical importance was attributed to ZIKV, once only few symptomatic cases were reported in some African and Southeast Asiatic countries. This situation changed in 2007, when a large outbreak was registered on the Yap Island, Micronesia, caused by the Asian ZIKV lineage. Between 2013 and 2014, ZIKV spread explosively and caused many outbreaks in different islands of the Southern Pacific Ocean and in 2015 autochthonous transmission was reported in Brazil. Currently, Brazil is the country with the highest number of ZIKV-positive cases in Latin America. Moreover, for the first time after the discovery of ZIKV, the Brazilian scientists are studying the possibility for the virus to cause severe congenital infection related to microcephaly and serious birth defects due to the time-spatial coincidence of the alarming increase of newborns with microcephaly and the Brazilian ZIKV epidemic. The present review summarizes recent information for ZIKV epidemiology, clinical picture, transmission, diagnosis and the consequences of this emerging virus in Brazil. (AU)

• Processo FAPESP: 09/16623-1 - Mecanismos moleculares e consequências clínicas da infecção causada pelo Parvovírus B19 e Citomegalovírus humanos em pacientes com hemoglobinopatias e hemofilia
• Beneficiário: Svetoslav Nanev Slavov
• Modalidade de apoio: Bolsas no Brasil - Pós-Doutorado